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Context: Nocturia is a prevalent symptom with varied aetiology and no consensus on treatment 
options. 
Objective: We systematically reviewed evidence comparing the benefits and harms of various 
treatment options for nocturia or nocturnal incontinence in women. 
Evidence acquisition:  Literature search was performed using Embase, Medline, Cochrane 
databases (from January 1, 1946 to September 26, 2017), following the methods detailed in the 
Cochrane Handbook. The protocol was registered with PROSPERO. Certainty of evidence was 
assessed with GRADE approach. 
Evidence synthesis: The literature search identified 3573 citations, of which 11 full text articles 
were included. 3 studies on desmopressin and 4 on antimuscarinics provided evidence of 
improving nocturia symptoms. 4 studies on behavioural treatment provided limited evidence 
and controversial results. 1 study on oestrogen did not prove the benefit of any mode of 
administration, and one small study on functional magnetic stimulation provided some evidence 
of effectiveness in nocturia. One RCT (141 participants) reported a statistically significant 
difference between the desmopressin and placebo group (desmopressin patients experienced 
0.75 (95% CI 0.47-1.03) nocturia episodes less than placebo; certainty of evidence = low). The 
only RCT on antimuscarinics in women with nocturia reported oxybutynin reduced the number 
of nocturia episodes by 0.3 (95% CI -0.02 to 0.62) versus placebo. In one RCT comparing 
tolterodine to the combination of tolterodine with behavioural therapy, there was significant 
change from baseline nocturnal incontinence episodes in both groups. 
Conclusions There is some evidence that desmopressin and antimuscarinics are effective 
treatment options for nocturia, however there is very limited evidence for other treatment 
options. The findings should be interpreted with caution as there were some methodological 
flaws in the included studies, particularly outcome heterogeneity. 
Patient summary This review identified several medical treatments for nocturia in women, 




Nocturia is defined by the International Continence Society (ICS) as “waking to pass urine 
during the main sleep period”. Nocturnal incontinence is a complaint of intermittent 
incontinence that occurs during the main period of sleep after the age of 3-5 at which bladder 
control usually occurs [1]. Nocturnal polyuria (NP) is defined as passing large volumes of urine 
during the main sleep period that should be quantified using a bladder diary [2]; some of the 
definitions propose thresholds like nocturnal urine volume greater than 20% to 33% of total 24-
hour urinary volume. 
Nocturia is a prevalent symptom in men and women of all age groups. This paper will focus on 
women only. According to Bosch and Weiss,  1 in 5 or 6 younger people consistently wake to 
void at least twice each night. Up to 60% of older people void 2 or more times nightly [3]. Age 
is one of the most important risk factors. There is some controversial evidence about gender as 
a risk factor. There is some evidence about association with metabolic syndrome, obesity, 
diabetes, cardiac disease, other conditions and ethnicity (African-American race) [4, 5]. 
Although nocturia is not a life-threatening condition itself, there is a risk of increased mortality 
in some patients due to hip fractures caused by risk of falls when getting up to urinate [6]. 
Economic burden of nocturia is important, frequently leading to repeated consultations, 
diagnostic procedures, medications and therapies with costs adding up with every patient. Sleep 
disturbance/bother and impact on quality of life are the most important reasons for 
consultation[7]. 
Concerning the optimal treatment of nocturia in women there is no consensus due to the 
multifactorial pathophysiology (common symptom in different diseases). The underlying 
causes may be urologic, e.g. LUTS, neurogenic voiding dysfunction; or non-urological in 
origin, such as chronic heart failure, sleep apnea and hormonal . [8] The question of optimal 
treatment was studied previously but evidence was limited [9-13]. Currently available 
treatments include antidiuretics and antimuscarinics. Desmopressin is an antidiuretic, working 
at the level of the renal collecting duct, binding to the V2 receptors present in the distal 
collecting tubules. It is thought to work in patients with nocturnal polyuria by decreasing 
diuresis. Muscarinic receptor antagonists or antimuscarinics such as darifenacin, fesoterodine, 
oxybutynin, propiverine, solifenacin, tolterodine, trospium chloride, block the activity of 
muscarinic acetylcholine receptor. Some of them are more specific to the M3-receptor, which 
is most prevalent in detrusor muscle; some are less specific and act on all receptor sub-types 
(M1, M2 and M3) leading to more side effects. 
There is no consensus on which treatment option is the most effective in women with nocturia 
or nocturnal incontinence. Furthermore, since the topic is not covered in the recent EAU 
Guidelines, the Urinary Incontinence Panel conducted a systematic review (SR) on female 
nocturia and female nocturnal incontinence to enable recommendations in a future version of 
the guidelines. In this study we systematically reviewed evidence for the most effective 
treatment of nocturia or nocturnal incontinence in terms of improving symptom severity and 
quality of life in adult women.  
 
2. Evidence acquisition  
This SR was undertaken under the auspices of the European Association of Urology (EAU). 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) guidance and the Cochrane Handbook for systematic reviews of interventions [14, 
15]. The protocol was registered at PROSPERO (CRD42017058997). 
The databases searched were the Embase, OVID Medline Epub Ahead of Print, In-Process & 
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R), EBM 
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Reviews - Cochrane Central Register of Controlled Trials, EBM Reviews - Cochrane Database 
of Systematic Reviews from 1946 to September 2017. Studies were limited to full text articles 
published in English, French, Spanish, Russian and German language. The complete search 
strategy is provided in Supplementary Material Appendix 1. The detailed PICO search strategy 
is shown in Table 1. 
Data collection and analysis 
The study selection process is described in Figure 1 [16]. All stages of selection were done with 
Covidence (www.covidence.org).  
Two review authors (DB and DA) independently assessed the risk of bias (RoB), using the 
Cochrane RoB assessment tool for RCTs [17]. Risk of bias in non-RCT was evaluated with an 
extra item to assess the risk of confounding [18, 19]. Study authors were contacted to provide 
missing information. Any disagreements were resolved by discussion or by consulting a third 
review author (IO). 
Meta-analysis, funnel plots interpretation or assessment of heterogeneity and sensitivity 
analyses were planned, but not feasible due to paucity of data. Furthermore, the studies used 
different dosages and modes of administration of drugs. Quantitative synthesis was not 
undertaken for non-randomized studies. Instead, we used the narrative synthesis [14, 20] 
approach to summarize the results. 
The GRADE approach was used for assessing the certainty of evidence. The following 
outcomes were selected for the “Summary of Findings” table:  
- Number/frequency of nocturia episodes;  
- NPI (NP index; nocturnal urine volume/24-h urine volume [%]); 
- nocturnal urinary volume 
- nocturnal urinary incontinence episodes 
 
3. Evidence synthesis 
3.1.Description of the included studies 
3573 references were identified for screening and 195 selected for full-text screening. The 
authors of 41 articles with mixed populations were contacted to get separate female data, but 
after 12 months with 2 reminders, data from only one study had been received, so it was decided 
to exclude these articles. The characteristics of 11 included studies are reported in 
Supplementary table. 
Risk of bias (RoB) in included studies 
The domains of RoB for the 11 included studies are summarized in Figure 2. All except one 
study showed high risk of bias in at least one of the seven domains that apply to RCT’s as well 
as non-RCT’s.  
Desmopressin: 
This is a synthetic analogue of the hormone vasopressin. It is most often used for management 
of nocturia due to nocturnal polyuria. We found 3 trials specifically conducted in women [21-
23], but more additional data could be extracted from mixed populations [9-11, 13].  
In the oldest study, by Hilton in 1982 [21], there were statistically significant differences in the 
main nocturia outcomes. Further studies in a mixed population supported that finding [9-11, 
13].  
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Lose [22] used desmopressin in doses 0.1, 0.2, 0.4 mg orally at bedtime after a dose-titration 
period, in participants that responded to the dose-titration phase. Of the 80 withdrawals after 
the dose-titration phase, only 8 patients lacked a pharmacological response. The authors 
randomized 144 women to desmopressin (N=72) or placebo (N=72) and after follow-up of 3 
weeks showed a benefit of desmopressin for all measured outcomes for nocturia (Table2). 
There was a difference in the number of nocturnal voids in favour of desmopressin, as well as 
for nocturnal diuresis. 
Yamaguchi [23] reported results of different doses of desmopressin separately for men and 
women (aged 55-75). A total of 58 women in 5 groups (12 in placebo, 12 in 10 µg, 11 in 25 µg, 
11 in 50 µg, 12 in 100 µg group, respectively) were followed for 4 weeks. The authors observed 
a dose-response relationship. In the gender comparison they found that female patients were 
more sensitive to desmopressin, so they propose to minimize the risk of hyponatraemia in 
women by using lower doses. There were statistically significant differences in the change in 
nocturnal urinary volumes in the following comparisons in favour of the higher desmopressin 
dose: 10µg vs 25µg and 10µg vs 100 µg. Also, there were differences in the NPI (nocturnal 
polyuria index) in following comparisons in favour of desmopressin over placebo or in favour 
of the higher desmopressin dose: placebo vs 25µg; placebo vs 100µg; 10µg vs 25µg; 10µg vs 
100µg. 
Unfortunately, we could not combine the three studies above in a meta-analysis because of 
different dosages and modes of administration. However, we generated a forest plot combining 
the main findings cited above for comparisons of desmopressin vs. placebo (Fig. 3). 
Desmopressin can be safely combined with antimuscarinics with a significant benefit in women 
with nocturnal polyuria, as shown by Rovner [24] in a post-hoc analysis of an RCT comparing 
3-month once-daily combination (desmopressin 25 μg/tolterodine 4mg; n=49) or monotherapy 
(tolterodine 4 mg/placebo; n=57). 
3.2.Antimuscarinics 
We found 4 RCTs of antimuscarinics such as oxybutynin 2.5 mg/day [25], tolterodine 4mg/day 
[24, 26, 27]. 
Johnson reported results of a secondary analysis from a prospective RCT [25]. In 131 women 
(aged 55-92) with nocturia followed up for 8 weeks they found that 46 women on 2.5 mg once 
a day immediate-release, with possibility to self-titrate oxybutynin, had less nocturia episodes 
than the 38 in the placebo group, but more episodes than the 47 patients in the behavioural 
treatment group. There was no statistically significant difference in nocturia episodes between 
oxybutynin and placebo group, but there was one in favour of behavioural treatment. 
Three selected studies on tolterodine in a female population did not include a placebo group but 
compared tolterodine monotherapy to some type of combination treatment. All 3 studies 
showed a significant change from baseline. Various other studies in mixed populations [9-11, 
13] showed comparable results.  
FitzGerald followed-up 305 women for 8 weeks in 2 groups: with tolterodine tartrate extended-
release capsules 4mg alone or in combination with behavioural training [26]. The authors 
observed small (in absolute numbers of episodes) but statistically significant differences (p < 
0.001) in mean nocturia frequency and nocturnal incontinence frequency as compared to 
baseline in both groups, but no difference between study treatment groups. 
Rovner performed a RCT in 97 women randomized to a 3-month once-daily combination 
(desmopressin 25 μg/tolterodine 4mg; n=49) or monotherapy (tolterodine 4mg/placebo; n=57) 
[24]. The significant changes in mean number of nocturnal voids from baseline was comparable 
between groups. In a post-hoc analysis in subgroups with/without nocturnal polyuria, the 
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authors probed the benefit of combination therapy, and there was no difference in the reduction 
of mean number of nocturnal voids. 
The study by Yuan was not an RCT, but a well-designed large comparative study[27]. They 
followed 407 women with OAB and nocturia for 4 weeks. The patients were given tolterodine 
2 mg twice a day as monotherapy in one group, and tolterodine 2 mg twice a day combined 
with estazolam 1 mg at night in the other group for 4 weeks, respectively. There were significant 
changes from baseline in both groups for the main outcomes, such as number of nocturia 
episodes. The tested combination included an agent to promote sleep (estazolam); the 
combination showed a significant benefit for women with OAB and nocturia compared to 
monotherapy: there were differences in number of nocturia episodes per night, urgency 
episodes in 24 hours, urgency incontinence episodes in 24 hours, voided volume per 
micturition. 
3.3.Oestrogen 
We only found one RCT investigating oestrogen for nocturia. Lose compared oestradiol-
releasing vaginal ring and oestriol vaginal pessary in 251 women (follow-up = 24 weeks) [28]. 
The authors estimated the subjective score of urgency, frequency, nocturia, dysuria, stress and 
urge incontinence. There was no difference between the treatment groups in the number of 
women reporting nocturia though they reported significant change from baseline in both 
treatment arms (for nocturia 51% and 54% responded to treatment respectively).  
3.4.Behavioural treatment 
Analyzing studies on behavioural treatment we found more heterogeneity in the results. While 
the studies by Johnson, Aslan and Lo [27, 32, 33] were favourable for behavioural treatment, 
FitzGerald [28] did not show a benefit of the addition of behavioural therapy to drug treatment. 
The heterogeneous character of behavioural therapy itself can explain these results, while the 
treatment also differed from site to site. 
Aslan studied 50 women aged 70-89, who were randomized to the treatment group (bladder 
training and Kegel exercises) or the control group, in equal proportion. Follow-up at a single 
site in Turkey was 6 months [32]. There was a significant decrease of the nocturia complaints 
in the treatment group compared to the control group between the 8-week and 6-month 
evaluations (p < 0.05, reported binary; certainty of evidence = very low). 
Lo conducted an RCT in only 24 women (aged ≥ 20 years), 12 in each group. A group with 
pelvic floor exercise was compared to a group receiving interferential therapy (transcutaneous 
electrical nerve stimulation) in addition to pelvic floor exercise. The treatment was given 3 
times a week for 4 weeks [29]. The authors did not reach planned recruitment due to limitation 
of resources, and there was no difference in the number of nocturia episodes as indicated in 
their results. Although they did not find significant changes between the groups (probably 
because of small number of participants), the differences before and after treatment were 
statistically significant in both groups. 
The study of Johnson was described above[25]. The authors found that the group with 
behavioural training (4 visits, anorectal and pelvic muscle biofeedback, teaching skills and 
strategies for dealing with incontinence and urgency) showed better results than the groups 
receiving placebo. There was a difference in number of nocturia episodes in favour of 
behavioural treatment, and also in favour of the behavioural treatment group over the 
oxybutynin group. 
FitzGerald reported the number of nocturia episodes and nocturnal incontinence episodes as a 
change from baseline [26]. The result of the change in number of nocturia episodes from 
baseline appears to favour the tolterodine plus behavioural therapy group, however 95%CI 
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touched the line of no difference. There was also no difference in the change in number of 
nocturnal incontinence episodes. In contrast to the Johnson study, FitzGerald, who added 
behavioural therapy to tolterodine 4 mg, did not show a significant benefit of behavioural 
treatment. The difference in outcome between these two studies can be explained by difference 
in age (Johnson studied older women, mean age 68, and in FitzGerald study mean age 56 years); 
also the patients in the FitzGerald study were less symptomatic (1.7 voids/night vs. 1.9 
voids/night in Johnson), and there were pharmacological differences between the drugs: 
immediate release of oxybutynin and sustained release formulation of tolterodine.  
3.5.Functional magnetic stimulation  
We identified one small, single-centre RCT in which functional magnetic stimulation (FMS) 
was compared with placebo (But 2005 [30]). But and colleagues recruited 39 women (aged 28-
70), who were randomly assigned to the FMS group (N=23) or placebo (16). They followed 
these patients for 2 months and reported a significant decrease in voiding frequency (from 9.0 
to 6.7, p = 0.0002), nocturia (from 2.6 to 1.4, p = 0.0007) and pad use (from 3.9 to 2.2, p = 
0.007) in the treatment group compared to the placebo group. 
3.6. Results on nocturnal incontinence  
We have found only one study that reported on the number of nocturnal incontinence episodes 




3.7.1. Principal findings 
Our systematic review confirms that desmopressin and antimuscarinics are effective treatment 
options for nocturia in women, whereas other options, such as behavioural treatment, hormonal 
therapy or functional magnetic stimulation, are controversial. Many of the studies had 
methodological flaws and provided conflicting results when evaluating the same treatment. 
Risk of bias in random sequence generation was judged to be high in 2 and unclear in 4 studies. 
Allocation concealment was judged unclear in 4 studies. This was considered while assessing 
the overall certainty of evidence. As a result, majority of the outcomes were either rated as 
“low” or “very low” when assessing the certainty using the GRADE approach. Therefore, the 
findings of this SR should be interpreted with caution. 
Although 3 reported studies on desmopressin [21-23] showed that this drug is more effective 
than placebo in women in terms of decreasing the number of nocturia episodes, there are two 
main issues to consider. First is a necessity of screening for hyponatremia at baseline, since this 
is a contraindication for antidiuretic therapy. A second issue that we observed in the largest 
study identified is a dose-titration phase before the full trial. This increases the likelihood of a 
positive outcome because non-responders were excluded at this stage. Furthermore, we may 
suppose that desmopressin is more effective in patients with nocturnal polyuria as the 
predominant cause of nocturia, although we did not find studies that had distinguished these 
patient sub-categories. 
Antimuscarinics showed some benefit in OAB-related nocturia. However, most studies in our 
search reported on a mixed but female-predominant (about 80%) population. For this reason, 
we did not include these studies in the final SR. We found only one study with comparison of 
antimuscarinics as monotherapy versus placebo in women only [25]. Other studies [24, 26, 27] 
reported comparison of antimuscarinics to some form of combination therapy but without a 
placebo group. We suggest considering subcategorizing OAB-related nocturia in trials with 
OAB medications, to study the possible benefit of antimuscarinics. 
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The above-mentioned studies show that the underlying pathophysiological mechanisms of 
nocturia that may vary from patient to patient are often not well addressed when recruiting 
patients to trials. Important etiologic factors to consider are sleep apnoea, cardiovascular 
disease, and diabetes mellitus. Ideally, nocturia should be treated with a cause-specific strategy. 
The question of subcategories of nocturia should be considered when designing new trials; the 
use of questionnaires only to select patients tends to lump these heterogeneous patient 
categories together. Therefore, conclusions derived from the studies in this systematic review 
should be regarded with caution. Furthermore, the issue of objective markers for nocturia, such 
as voiding diaries, versus subjective patient perception (questionnaires) might have an impact 
on the results. This issue could not be further addressed in this review because of lack of data. 
3.7.2. Recommendations for future research 
Additional research is needed to examine other options for the treatment of nocturia and 
nocturnal incontinence in women. Many studies were undertaken in a mixed population and we 
suggest that authors report their results for men and women separately because the underlying 
pathophysiology varies significantly between the two genders. We also highly recommend 
classifying the underlying symptomatology as nocturia or nocturnal polyuria, using standard 
ICS definitions.  
We would like to emphasize the lack of long-term outcomes and large studies in female patients. 
Some outcomes are statistically significant, but it is unclear whether they are clinically relevant. 
We recommend the professional community to discuss and to determine minimally important 
difference (the smallest change in a treatment outcome that an individual patient would identify 
as important and which would indicate a change in the patient's management) in the number of 
nocturia episodes per night. Furthermore, no core outcome set for nocturia can be found in the 
COMET database; therefore, we recommend its development. 
Many identified studies reported combination treatments; this causes a problem of detecting 
what type of treatment is primarily responsible for the outcome; therefore, we recommend 
designing trials with monotherapies for comparison. This issue is particularly relevant in case 
of behavioural treatment, usually combined with lifestyle changes: protocols are often 
heterogeneous from site to site, which complicates generalisation of the outcomes.  
Strength and limitations of the review 
The main strength of this SR is that it is the first comprehensive literature search for all 
treatment options for nocturia in adult women specifically, using a robust and transparent 
methodological approach based on the Cochrane handbook. 
During the full-text screening we realized that the inclusion of studies with nocturia as a 
secondary outcome led to a high level of heterogeneity among the studies and the impossibility 
to derive conclusions from this selection. We had to make an amendment in the protocol: after 
discussion in the EAU UI Guidelines Panel, studies with nocturia as a secondary outcome were 
excluded because they did not focus on the treatment of nocturia patients.  
We did not include studies with mixed populations, even if the female population was more 
than 80-90% of the total, because randomization was done in the whole population, leading to 
imbalanced groups. During full-text screening 60 articles with mixed population were retrieved. 
In order to maximize the possibility to include as many female patients as possible in the review, 
the decision was made to contact authors for separate female data. The first letters were sent on 
the 28th of June 2018; unfortunately, only one author responded and since we had decided to 
analyse this type of data separately, we finally decided not to use the data of this author in the 
review. 
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Major limitations of the review include significant heterogeneity among the studies identified. 
Many of the evaluated studies on desmopressin used a dose titration phase, which may represent 
another source of bias. 
Whilst we identified only one study that reported treatment of nocturnal incontinence in 
women, we could not make any recommendations on this subject. There is no consensus about 
definition of nocturnal incontinence; the last ICS report on standardization of terminology did 
not include this term; instead, the term “enuresis” was proposed (included in our search strategy 
as well). It may be possible that patients with nocturia do not have nocturnal incontinence, 
because they wake up before leakage occurs; therefore, nocturia, which is getting up to void at 
night, may protect against nocturnal incontinence because the critical bladder volume is not 
reached.  
 
4. Conclusions  
Nocturia is a common symptom that can be associated with various diseases. Treatment choice 
should be made after thorough clinical evaluation of all possible causes. RCT evidence supports 
of the use of desmopressin in the management of nocturia associated with nocturnal polyuria, 
with careful serum sodium monitoring. RCT evidence also supports the use of antimuscarinic 
drugs for nocturia associated with symptoms of overactive bladder. Behavioural treatments may 
be considered as a non-invasive conservative measure for nocturia management, but the 
evidence is of low quality, weak and controversial. Other treatment options cannot be 
recommended due to lack of evidence or very low quality of evidence. We cannot provide any 




Table 1. PICO search strategy 
P Population Inclusion criteria: 
• Adult women (≥18 years old) categorised within the following symptom groups:  
o Nocturia as the primary presentation (i.e. nocturia as the predominant 
bothersome symptom)  
o Nocturia as a secondary component of lower urinary tract symptoms (LUTS) 
i.e. LUTS including nocturia  
o Nocturnal incontinence as a secondary component of incontinence  
o Nocturnal polyuria (following International Continence Society definition, or 
as defined by trialist)  
Exclusion criteria: 
• Neuro-urology patients such as spinal cord injury patients, multiple sclerosis, 
myelomeningocele and nerve tube defects, Parkinson’s disease, Alzheimer’s disease 
(according to EAU Guidelines [13]) 
• Children 
I Intervention • Medical treatment (we included all published doses and schedules): anticholinergic 
drug, mirabegron, desmopressin, diuretics (all types), sleep promoting agents (e.g. 
hypnotics – diazepam, nitrazepam), oestrogen (topical or hormone replacement 
therapy), treatment for pain (e.g. sodium hyaluronate bladder instillations), 
phytotherapy (e.g. herbal treatment) 
• Surgical treatment: botulinum toxin Type A, neuromodulation (sacral nerve 
stimulation, etc.), neurostimulation (e.g. Parasacral Transcutaneous Electrical Neural 
Stimulation (PTENS)), surgery to relieve bladder outlet obstruction in women  
• Lifestyle modification (e.g. moderating fluid intake at night, leg elevation, avoiding 
caffeine, etc.) 
• Any other treatment (e.g. acupuncture, Continuous Positive Airway Pressure machine 
(CPAP), etc.), compression stockings, psychotherapy, hypnotherapy   
C Comparator • Placebo 
• No treatment 
• Other experimental treatment as listed above under intervention 
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O Outcomes No core outcome set for nocturia was found in the COMET database 
 The primary benefit outcome was  
• improvement in symptom severity/number of voids*/ for nocturia (outcome 
measure as defined by trialist).  
The primary harm outcomes were:  
• Adverse events* of treatment (ad hoc listing of events, e.g. dry eyes, blurring of 
vision, constipation, etc.), and events leading to potential harm (e.g. hyponatremia, 
voiding difficulties)  
• Any other outcomes judged relevant by the review author team.  
 
Secondary outcomes:  
• Night-time incontinence episodes*  
• Quality of life* (measured by validated questionnaire (such as IPSS, ICIQ-SF), at 
any time point)  
• Sleep quality (measured by validated questionnaire, at any time point)  
• Global improvement scales (not specific to incontinence, pain or sexual function) 
(measured by validated questionnaire (SF-Qualiveen), at any time point)  
• Healthcare resource use (QALY)  
• Bladder function (measured by validated questionnaire or by urodynamic, or by 
voiding diary, at any time point)  





Table 2. Summary of findings; Desmopressin versus placebo 
Desmopressin compared to Placebo for nocturia or nocturnal incontinence in terms of 
improving symptom severity and quality of life in adult women?  
Patient or population: nocturia or nocturnal incontinence in terms of improving symptom severity and quality of life in women?  
Setting: outpatient department (multicenter study) 
Intervention: Desmopressin  
Comparison: Placebo  
Outcomes 
Anticipated absolute effects* 
(95% CI)  Relative 
effect 














voids - 3 
weeks  
The mean no. 
of nocturnal 
voids - 3 
weeks was 0  
The mean no. 
of nocturnal 
voids - 3 
weeks in the 
intervention 
group was 0,75 
lower (1,03 
lower to 0,47 
lower)  
-  141 (1 RCT)  
⨁⨁ 
LOW a  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative 
effect of the intervention (and its 95% CI).  
 
CI: Confidence interval; MD: Mean difference  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, 
but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect  
 
Explanations 
a. Downgraded two levels due to following reasons: random sequence generation was done by pharmaceutical company, outcome assessors 
were not blinded, supported by a grant from pharmaceutical company, and "patients with no pharmacological response during dose titration 





































Figure 1. PRISMA flow diagram 
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searching 






















Additional records identified through 
other sources 
(n = 0) 
Records after duplicates removed 
(n = 3475) 
Records screened 
(DB,DA,VS) 
(n = 3475) 
Records excluded 
(n = 3193) 
Full-text articles assessed for 
eligibility (DB,DA,VS) 
(n = 281) Full-text articles excluded, with reasons (n = 270) 
• 33 Not relevant study design 
• 31 Conference abstract 
• 67 Not relevant outcomes 
• 22 Language 
• 68 Not relevant patient population 
• 15 Inconclusive Data 
• 7 Not relevant comparator 
• 6 Pediatric population 
• 8 Double record 
• 5 Not relevant intervention 
• 4 Letter to editor/reply 
• 2 Not relevant setting 
• 2 Clinical trial entry 
Studies included in 
qualitative synthesis  
(n = 11) 
Studies included in 
quantitative synthesis (meta-
analysis) 









Figure 2. Risk of bias summary according to the judgment of the review authors on 
each risk of bias item for each study included: (a) – for RCT studies, (b) – is for NRS. 
Key : red “-” is for high risk of bias, yellow “?” is for unclear risk of bias, green “+” is 











Table 3. Key characteristics of included studies assessing outcomes 













Hilton et al 1982 17 Desmopressin 
(DDAVP) 20 µg 
Placebo Single site, 
cross-over 




95% CI 204.53 
to 43.47 ml 
lower 
100% Low 




lower, 95% CI 
1.44 lower to 
0.10 higher  
100% Low 
Lose et al 2003 18 Desmopressin 
(0.1, 0.2, 0.4 mg 







141 57 (21-89) 3 weeks Nocturnal 
urinary 
frequency  
0.75 lower, 95% 
CI 1.03 lower to 
0.47 lower 
100% Low 




lower, 95% CI 





2013 19 Desmopressin 













higher, 95% CI 








 23  4 weeks  MD 143.26 ml 
higher, 95% CI 
20.52 higher to 
266 higher 
100% Low 
   placebo desmopressin 25 
µg 






higher, 95% CI 
1.41 higher to 
14.09 higher 
100% Low 
   placebo desmopressin 100 
µg 
 22    MD 6.78 higher, 95% CI 
1.02 higher to 
12.54 higher 
100% Low 




 21    8.54 higher, 95% CI 2.66 
higher to 14.42 
higher 
100% Low 




 23    7.57 higher, 95% CI 2.31 
















84 68 (55-92) 8 weeks number of 
nocturia 
episodes 
MD 0.30 lower, 
95% CI 0.62 




   Behavioural 
Treatment 
2.5 mg once a day 
immediate-release 
oxybutynin 
 93   number of nocturia 
episodes 
0.30 lower, 95% 



























95% CI 0.00 to 
0.52 higher 
100% moderate 




95% CI 0.08 





2018 20 Desmopressin 
25 μg + 
Tolterodine 4 
mg 
Tolterodine 4 mg: multicentre 
RCT 






0.34 lower, 95% 
CI 0.80 lower to 
0.12 higher 
100% moderate 
Yuan et al 2011 23 Tolterodine 4 
mg + Estazolam 
1mg  










4 weeks Number of 
nocturnal voids 
MD 1.20 lower, 
95% CI 1.28 
lower to 1.12 
lower 
100% Very low 
Oestrogens 











RR 0.94, 95% 




Aslan et al 2008 32 Bladder training 
+ Kegel 
exercises 
Control Single site 
RCT 












decrease in the 
treatment group 






 Very low 












24 Only per 
group, 
mean 
(SD): 52.1  
(17.5) 55.1 
(15.1) 
4 weeks number of 
nocturia 
episodes 
MD 0.54 lower, 
95% CI 1.3 




100% Very low 
Johnson et 
al 
2005 21 Behavioural 
Treatment 





84 68 (55-92) 8 weeks number of 
nocturia 
episodes 
MD 0.60 lower, 
95% CI 0.88 
lower to 0.32 
lower 
100% moderate 
   Behavioural 
Treatment 
2.5 mg once a day 
immediate-release 
oxybutynin 
     0.30 lower, 95% 
























95% CI 0.00 to 
0.52 higher 
100% low 
      218   number of nocturnal 
MD 0.06 





0.08 lower to 
0.20 higher 
Functional magnetic stimulation  










from 2.6 to 1.4, 
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